The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis.

Isabel MonteiroValerio NicolellaMariano FiorenzaFederica NovarellaAntonio CarotenutoRoberta LanzilloLucia MaurielloGiulia ScaliaGiuseppe CastaldoDaniela TerraccianoVincenzo Brescia MorraMarcello Moccia

Published in: Journal of neurology (2024)

Wearing-off is common in people with MS treated with ocrelizumab, and is associated with reduced immunomodulation (higher T lymphocytes) and increased neuroaxonal damage, suggesting reduced treatment response.

Keyphrases

multiple sclerosis
oxidative stress
mass spectrometry
white matter
newly diagnosed